RBC Europe’s Supernus Pharmaceuticals SUPN Stock Holding History

RBC Europe’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-64	Closed	-$2.56K	–	1158
2017 Q3	$2.56K	Buy	+64	New	+$2.77K	﹤0.01%	1043

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

RBC Europe's SUPN Position: Q4 2017 in Review

RBC Europe sold out of Supernus Pharmaceuticals (SUPN) in Q4 2017, closing a stake of 64 shares — an estimated $2.56K sold.

RBC Europe first reported a position in SUPN in Q3 2017 and held it in 1 quarter. The position peaked at $2.56K in Q3 2017. 297 funds tracked by Wall St. Rank hold SUPN as of Q4 2017.

RBC Europe reported no remaining Supernus Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
RBC Europe sold 64 Supernus Pharmaceuticals shares in Q4 2017, an estimated $2.56K.
RBC Europe first reported a position in Supernus Pharmaceuticals in Q3 2017 and held it in 1 quarter.
RBC Europe's Supernus Pharmaceuticals position peaked at $2.56K in Q3 2017.
297 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2017.

Based on RBC Europe's 13F filing for Q4 2017, filed 9 Nov 2023.